Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Anemia 1

Interventions

Rituximab 17Cyclophosphamide 8zanubrutinib 7Bendamustine Hydrochloride 7obinutuzumab 6Lenalidomide 6venetoclax 5blinatumomab 5acalabrutinib 5Vincristine 5fludarabine 4Prednisone 4Methotrexate 4Doxorubicin 4Cytarabine 4Brentuximab Vedotin 4ibrutinib 3Specimen Handling 3Dexamethasone 3Crizotinib 3tisagenlecleucel 2tafasitamab 2polatuzumab vedotin 2pirtobrutinib 2pegaspargase 2idelalisib 2duvelisib 2axicabtagene ciloleucel 2avapritinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × fludarabine phosphate × Lymphoid × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡